This introduction to gene therapy explains how genes work, and how gene therapy can be used to create new therapies for hemophilia.
Advancements in gene therapy are happening at a fast clip. Having a solid understanding of this technology is important to patients, caregivers and families. Join us for an in-depth discussion of gene therapy including historical aspects, key terms…
The realization that gene therapy could be just around the corner is both daunting and exciting. Join us for a balanced, patient-centric discussion on gene therapy from multiple perspectives: a provider, a patient in a gene therapy clinical trial, a…
We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on December 2nd starting at 7:00 pm ET. This meeting will discuss NHF business operations and decisions and…
Historically, data on infants and toddlers (ITs) with von Willebrand disease (VWD), particularly relevant to bleeding patterns, has been lacking. To address this absence of data, a team of researchers from the U.S. Hemophilia Treatment Center…
Sigilon Therapeutics today reported a new development in the company’s phase 1/2 clinical study of SIG-001 in individuals with severe or moderately severe hemophilia. This follows the events of this past summer when the U.S. Food and Drug…
NHF’s Washington Days is an opportunity for people affected by inherited blood disorders to advocate for issues that are important to them. In 2021, Washington Days had more than 400 volunteer advocates from 45 states that met with legislators and…
PRESS RELEASE
FOR IMMEDIATE RELEASE
MEDIA CONTACT:
Ilana Ostrin
212-328-3769
iostrin@hemophilia.org
NHF’s newest scholarship honors future leaders, advocates, and…
Pase las tardes de los Martes con el equipo de Educación para el Empoderamiento de NHF. A lo largo de las próximas cuatro semanas, presentaremos talleres de nuestras nuevas series educativas, que abarcan una gran variedad de temas. Cada serie…